Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US7097823

Title:High dose radionuclide complexes for bone marrow suppression
Inventors:Fritzberg, Alan R.; Olga, WA, USA
Abrams, Paul G.; Seattle, WA, USA
Tatalick, Lauren Marie; Redmond, WA, USA
Thoelke, Kent R.; Seattle, WA, USA
Bryan, James Kyle; Seattle, WA, USA
Hylarides, Mark D.; Stanwood, WA, USA
John, Elizabeth K.; San Diego, CA, USA
Summary:This invention describes a method for the treatment of osteomyelitis, in which a composition comprising a ligand-complexed radionuclide is administered to a subject suffering from osteomyelitis. Methods are also disclosed for the suppression of bone marrow in the treatment of cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid. Methods are also described for the augmentation of the subjectís bone marrow following such treatment, via transplantation with purged autologous or matched allogeneic bone marrow, including peripheral blood stem cells, and/or by treatment with bone marrow-stimulating agents.
Abstract:The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
US Patent Website:Click Here for Full Text of Patent
Title Number:US7097823
Application Number:US2004000784476
Date Filed:23/02/2004
Date Published:29/08/2006
Assignee:NeoRx Corporation, Seattle, WA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021